Baxdrostat Lowers Blood Pressure and Cuts Kidney-Damage Markers in High-Risk CKD Patients

A Phase 2, randomized, double-blind, placebo-controlled study evaluated baxdrostat, an investigational aldosterone-synthase inhibitor, in adults with chronic kidney disease (CKD) and uncontrolled hypertension. Conducted at 71 U.S. sites, the trial enrolled 195 participants; 192 were randomized to low-dose baxdrostat (0.5 -> 1 mg), high-dose baxdrostat (2 -> 4 mg), or placebo, all added to standard ACE-inhibitor or ARB therapy. After 26 weeks, systolic blood pressure fell 8.1 mm Hg more than with placebo (?5 % reduction). Urine albumin-creatinine ratios dropped 55 % versus placebo, an effect comparable to agents known to slow CKD progression.

SciTechDaily

The cohort had a mean age of 66 years; 32 % were women, 40 % non-Hispanic white, and 80 % had type 2 diabetes. Baseline systolic pressure averaged 151 mm Hg despite maximal ACE-inhibitor or ARB dosing. Mean estimated glomerular filtration rate was 44 mL/min/1.73 m², and average urine albumin-creatinine ratio was 714 mg/g, indicating advanced CKD but not end-stage failure.

SciTechDaily

Elevated serum potassium occurred in 41 % of baxdrostat recipients versus 5 % on placebo, most cases described as mild-to-moderate. Serious adverse events were reported in 9 % of baxdrostat participants compared with 3 % on placebo; no deaths or unexpected adverse events were recorded.

SciTechDaily

Lead investigator Jamie P. Dwyer, M.D., emphasized that the results “are encouraging for people living with chronic kidney disease and high blood pressure, two conditions that often go hand-in-hand and create a dangerous cycle.” Independent nephrology expert Jordana B. Cohen, M.D., M.S.C.E., noted that the findings “are reassuring that this new class of antihypertensive medications are likely to have both kidney- and cardio-protective benefits and to be safe and effective for broad patient populations.” AstraZeneca, the drug’s developer, reported that Phase 3 trials are underway, including combination studies with dapagliflozin, and that data are being shared with regulatory authorities.

SciTechDaily

Safety signals—particularly the high incidence of hyperkalaemia and a higher rate of serious adverse events—temper enthusiasm and underscore the need for larger, longer-term studies. The drug remains unapproved by the U.S. Food and Drug Administration, and the Phase 2 trial’s exploratory albumin analysis does not establish causality for renal protection.

SciTechDaily

While the trial demonstrated short-term blood-pressure and albumin reductions, it did not assess hard renal outcomes such as sustained eGFR decline, kidney failure, or cardiovascular events. Ongoing Phase 3 investigations aim to fill these gaps, but current data cannot confirm long-term kidney-failure prevention.

SciTechDaily

• “These findings are encouraging for people living with chronic kidney disease and high blood pressure, two conditions that often go hand-in-hand and create a dangerous cycle,” — Jamie P. Dwyer, M.D., University of Utah Health

SciTechDaily

• “The reduction in urine albumin gives us hope that baxdrostat may also help delay kidney damage. This potential is now being tested in two large Phase 3 trials to determine if baxdrostat delays the progression of kidney disease,” — Jamie P. Dwyer, M.D.

SciTechDaily

• “These new findings are reassuring that this new class of antihypertensive medications are likely to have both kidney- and cardio-protective benefits and to be safe and effective for broad patient populations,” — Jordana B. Cohen, M.D., M.S.C.E.

SciTechDaily

• “Patients with chronic kidney disease were historically often excluded from drug studies. It is particularly reassuring to know that patients with chronic kidney disease, who have very high rates of hypertension and elevated renin-angiotensin aldosterone activity, were represented in their own study, tolerated the medication well, and had both blood pressure and albuminuric benefits. This medication class could be a game changer in the management of hypertension in this patient group.” — Jordana B. Cohen, M.D., M.S.C.E.

SciTechDaily

Baxdrostat is now being evaluated in two large Phase 3 programs: the BaxHTN and Bax24 trials, which assess seated and ambulatory blood-pressure reductions in resistant hypertension, and combination studies with dapagliflozin that will monitor major kidney and cardiovascular outcomes over 24 months. Results from these trials will determine whether regulatory approval and broader clinical use are warranted.

SciTechDaily